Proroxan

Proroxan

Clinical data
Other names	Pyrroxane, Pirroksan
Legal status
Legal status	Rx in Russia
Identifiers
IUPAC name 1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-(3-phenylpyrrolidin-1-yl)propan-1-one
CAS Number	33743-96-3
PubChem CID	36303
UNII	T5WT3QN49G
KEGG	D05641
CompTox Dashboard (EPA)	DTXSID9046285
Chemical and physical data
Formula	C21H23NO3
Molar mass	337.419 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4
InChI InChI=1S/C21H23NO3/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16/h1-7,14,18H,8-13,15H2 Key:GZIISXIDAZYOLI-UHFFFAOYSA-N

Proroxan (INN; also known as pyrroxane and pirroksan) is a pharmaceutical drug used as an antihypertensive and in the treatment of Ménière's disease, motion sickness, and allergic dermatitis.

Proroxan is a non-selective alpha-blocker (α-adrenoreceptor antagonist).

Proroxan was developed in the 1970s at the Institute of Toxicology of the USSR Ministry of Health and today is primarily used in Russia. Though originally developed as an antihypertensive, its use can lead to a decrease in alcohol and drug consumption. Currently proroxan is used almost exclusively in psychiatry, narcology, and neurology.